La scintigraphie par 18f-fluorodésoxyglucose (fdg) dans les cancers mammaires

Abstract

Fluorine 18-fluorodecxyglucose is concentrated in malignant cells and can be detected with positror, emission tomography (PET). In breast disease, this non invasive method seems to be useful in cases where the initial staging (clinical examination, mammagraphy, fine needle aspiration of palpable mass) is insufficient. A large number of published studies have demonstrated that PET scan is better than conventional imaging in the initial staging (primary tumour, lymph node involvement, distant metastases), in the evaluation of fatty and dense mammary gland or mastopathy, in the detection of recurrence in previously treated breast cancer (surgery, radiation therapy, brachytherapy, mammaplasty) and in the detection of occult metastases suspected on a raising tumour marker. PET scan performances must be confirmed and would become a useful diagnostic test in breast cancer as well as a necessary tool in the assessment of the therapeutic efficacy.